Lorenz has 25 years of experience in the pharmaceutical and biotechnology industry, spanning drug discovery and clinical development in areas including molecular biology, molecular imaging, antibodies, cell and gene therapy, and gene editing. Lorenz was most recently Chief Technology Officer at GE Healthcare, where he was responsible for leading the company’s global R&D strategy. Prior to this, he held senior leadership roles at AstraZeneca Plc, Novartis Pharma AG and Bayer AG. Lorenz is a lecturer for Biochemistry at the Martin-Luther University, Germany, and is a member of several Scientific Advisory Boards.
Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Lorenz is a highly regarded member of the scientific community and is a fantastic addition to the Syncona team. His knowledge and experience in the sector will enhance our search for best-in-class science that has commercial prospects and the potential to make meaningful differences to patients.”
Lorenz Mayr, Entrepreneur in Residence of Syncona Investment Management Limited, added: “I look forward to joining the team at Syncona and helping them seek opportunities to found new companies. Syncona has an excellent track record and I’m excited to be part of a process that brings exceptional science from concept to clinic.”
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.